Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with
global public health impact affecting more than 25% of the global population. NAFLD is …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

The global prevalence of nonalcoholic fatty liver disease (NAFLD) has dramatically
increased in parallel with the epidemic of obesity. Controversy has emerged around dietary …

This update of evidence-based guidelines (GL) aims to translate current evidence and
expert opinion into recommendations for multidisciplinary teams responsible for the optimal …

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading
cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease …

Background and aim Non-alcoholic fatty liver disease (NAFLD), affecting up to around 30%
of the world's adult population, causes considerable liver-related and extrahepatic morbidity …